Lund University Hospital
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1768-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.skane.se/sus
Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02699424
- Locations
- 🇸🇪
Lund University Hospital, Lund, Sweden
Phantom Limb Pain: Efficacy of Non-invasive Sensory Feedback Through the Prosthesis
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT02589080
- Locations
- 🇸🇪
Fredrik Sebelius, Lund, Sweden
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02460276
- Locations
- 🇸🇪
Lund University Hospital, Lund, Sweden
🇸🇪Uppsala Akademiska Hospital, Uppsala, Sweden
🇩🇰Rigshospitalet, Copenhagen, Denmark
Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT02246725
- Locations
- 🇸🇪
Lund University Hospital, Lund, Sweden
Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT02241499
- Locations
- 🇸🇪
Lund University Hospital, Department of Oncology, Lund, Sweden
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02144623
- Locations
- 🇸🇪
Lund University Hospital, Department of Oncology, Lund, Sweden
The Swedish Study on Paleolithic Diet for Type 2 Diabetes
Not Applicable
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Lund University Hospital
- Registration Number
- NCT01999452
- Locations
- 🇸🇪
Center for Primary Health Care Research, Clinical Research Centre (CRC), hus 28, plan 11, Jan Waldenströms gata 35, Malmö, Skåne, Sweden
A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 298
- Registration Number
- NCT01969877
- Locations
- 🇸🇪
University Hospital Linköping, Linköping, Sweden
🇸🇪County Hospital Ryhov, Jönköping, Sweden
🇸🇪Central Hospital, Karlstad, Sweden
Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT01674582
- Locations
- 🇸🇪
Lund University Hospital, Lund, Sweden
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01622439
- Locations
- 🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden
© Copyright 2024. All Rights Reserved by MedPath